In this edition of our NCIA Committee Insights series originally aired on Tuesday, March 1, 2022 members of NCIA’s Scientific Advisory Committee convened a panel of leading clinical, regulatory and cannabis technology experts to lead a very timely discussion surrounding cannabis and COVID-19.
This webinar gave an overview of the effects of COVID-19 on the body with a discussion on the research related to cannabis based treatments.
Presentation Slide Deck: https://bit.ly/3tjbcvi
• Learn about COVID-19 and how it infects the mammalian body’s organ systems.
• Discuss the endocannabinoid systems role in the immune response and how research supports its role in COVID-19.
• Outline implications of cannabinoid treatments based on available research including the most recent acidic cannabinoid study that has been all over the media.
• Identify areas of interest for future research.
Dr. Paloma Lehfeldt, MD, MA
Senior Director of Clinical Science and Partnerships
Goodness Growth Holdings
Owner and President
Cannapy Health LLC / Postolova Acupuncture Group, Inc.
Director / CEO
Lucid Lab Group / Flowe Technology